BridgeBio Pharma Announces Secondary Offering of 5M Shares by KKR

What Happened

• BridgeBio Pharma, Inc. filed an 8-K reporting that on August 13, 2026 it entered an underwriting agreement with William Blair, Goldman Sachs and KKR Capital Markets to sell 5,000,000 existing shares held by KKR Genetic Disorder L.P. The shares were priced at $78.00 each and the sale was expected to close on August 17, 2026. The Company stated it will receive no proceeds from this sale. The offering was made under the Company’s effective Form S-3ASR shelf registration.

Key Details

• Seller: KKR Genetic Disorder L.P. (selling stockholder).
• Shares offered: 5,000,000 common shares.
• Price to public: $78.00 per share; Company receives no proceeds (secondary offering).
• Underwriting reps: William Blair & Company, Goldman Sachs & Co. LLC, KKR Capital Markets LLC.
• Agreement dated August 13, 2026; prospectus supplement filed August 14, 2026; expected closing August 17, 2026.

Why It Matters

• This is a secondary offering of existing shares (not a capital raise for the company), so BridgeBio’s cash balance is unaffected. However, the transaction increases the number of shares available to public investors, which can affect market supply and share price dynamics. Investors should note this change in share float and monitor trading and future company disclosures (press releases and SEC filings) for any further updates.